Pulmatrix Company Leadership
| PULM Stock | USD 5.62 0.19 3.50% |
About 66 percent of all Pulmatrix's insiders are acquiring. The analysis of insiders' sentiment of trading Pulmatrix stock suggests that many insiders are confidant at this time. Pulmatrix employs about 22 people. The company is managed by 6 executives with a total tenure of roughly 52 years, averaging almost 8.0 years of service per executive, having 3.67 employees per reported executive.
Pulmatrix's Insider Buying Vs Selling
66
Selling | Buying |
Latest Trades
| 2015-06-16 | Steven Gillis | Acquired 72750 @ 6.88 | View | ||
| 2015-06-15 | Terrance Mcguire | Acquired 106693 @ 6.88 | View | ||
| 2015-03-23 | Innovative Sciences In Oculus | Disposed 350000 @ 2.75 | View |
Monitoring Pulmatrix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Pulmatrix |
Pulmatrix's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pulmatrix's future performance. Based on our forecasts, it is anticipated that Pulmatrix will maintain a workforce of about 20 employees by December 2024.Pulmatrix Management Team Effectiveness
The company has return on total asset (ROA) of (0.2999) % which means that it has lost $0.2999 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5899) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Non Currrent Assets Other are very stable compared to the past year. As of the 21st of November 2024, Total Current Assets is likely to grow to about 22.2 M, while Non Current Assets Total are likely to drop about 8.2 M.As of the 21st of November 2024, Common Stock Shares Outstanding is likely to grow to about 3.8 M, while Net Loss is likely to drop (17.8 M).
Pulmatrix Workforce Comparison
Pulmatrix is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 56,245. Pulmatrix adds roughly 22.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.95) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.8) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.8. Pulmatrix Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pulmatrix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2020-09-01 | 1.0 | 8 | 8 | 55,602 | 55,602 |
| 2019-06-01 | 4.0 | 8 | 2 | 570,000 | 1,247 |
| 2017-03-01 | 5.0 | 10 | 2 | 337,988 | 6,788 |
| 2015-12-01 | 1.0 | 2 | 2 | 92,299 | 760.00 |
| 2015-06-01 | 40.5 | 81 | 2 | 15,052,238 | 1,650,000 |
Pulmatrix Notable Stakeholders
A Pulmatrix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pulmatrix often face trade-offs trying to please all of them. Pulmatrix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pulmatrix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Teofilo MBA | CEO President | Profile | |
| MBA CMA | Interim Officer | Profile | |
| Alexander Klibanov | Founder | Profile | |
| Margaret MD | Chief Officer | Profile | |
| David JD | Advisor | Profile | |
| Aidan Curran | VP Affairs | Profile |
About Pulmatrix Management Performance
The success or failure of an entity such as Pulmatrix often depends on how effective the management is. Pulmatrix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pulmatrix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pulmatrix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.78) | (0.82) |
Pulmatrix Workforce Analysis
Traditionally, organizations such as Pulmatrix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pulmatrix within its industry.Pulmatrix Manpower Efficiency
Return on Pulmatrix Manpower
| Revenue Per Employee | 331.7K | |
| Revenue Per Executive | 1.2M | |
| Net Loss Per Employee | 641.9K | |
| Net Loss Per Executive | 2.4M | |
| Working Capital Per Employee | 769.7K | |
| Working Capital Per Executive | 2.8M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.